ABBV
Price
$167.28
Change
-$0.55 (-0.33%)
Updated
Apr 25, 6:59 PM EST
One day until earnings call
BMY
Price
$44.68
Change
-$4.17 (-8.54%)
Updated
Apr 25, 6:59 PM EST
Earnings call today
Ad is loading...

Analysis and predictions ABBV vs BMY

Header iconABBV vs BMY Comparison
Open Charts ABBV vs BMYBanner chart's image
ABBVIE
Price$167.28
Change-$0.55 (-0.33%)
Volume$1.75M
CapitalizationN/A
Bristol-Myers Squibb
Price$44.68
Change-$4.17 (-8.54%)
Volume$22.5M
CapitalizationN/A
View a ticker or compare two or three
ABBV vs BMY Comparison Chart

Loading...

ABBVDaily Signal changed days agoGain/Loss if shorted
 
Show more...
BMYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ABBV vs. BMY commentary
Apr 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and BMY is a Hold.

COMPARISON
Comparison
Apr 26, 2024
Stock price -- (ABBV: $167.80 vs. BMY: $48.86)
Brand notoriety: ABBV and BMY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 72% vs. BMY: 105%
Market capitalization -- ABBV: $322.43B vs. BMY: $109.66B
ABBV [@Pharmaceuticals: Major] is valued at $322.43B. BMY’s [@Pharmaceuticals: Major] market capitalization is $109.66B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whileBMY’s FA Score has 1 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • BMY’s FA Score: 1 green, 4 red.
According to our system of comparison, ABBV is a better buy in the long-term than BMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 5 TA indicator(s) are bullish while BMY’s TA Score has 4 bullish TA indicator(s).

  • ABBV’s TA Score: 5 bullish, 5 bearish.
  • BMY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than BMY.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а +2.16% price change this week, while BMY (@Pharmaceuticals: Major) price change was +2.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.10%. For the same industry, the average monthly price growth was -4.34%, and the average quarterly price growth was +0.52%.

Reported Earning Dates

ABBV is expected to report earnings on Jul 26, 2024.

BMY is expected to report earnings on Jul 26, 2024.

Industries' Descriptions

@Pharmaceuticals: Major (+1.10% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
A.I.dvisor published
a Summary for ABBV with price predictions.
OPEN
A.I.dvisor published
a Summary for BMY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ABBV($322B) has a higher market cap than BMY($110B). ABBV has higher P/E ratio than BMY: ABBV (66.46) vs BMY (13.73). ABBV YTD gains are higher at: 9.314 vs. BMY (-3.670). BMY has higher annual earnings (EBITDA): 19.4B vs. ABBV (17.2B). ABBV (12.8B) and BMY (12.3B) have equal amount of cash in the bank . BMY has less debt than ABBV: BMY (41.5B) vs ABBV (59.4B). ABBV has higher revenues than BMY: ABBV (54.3B) vs BMY (45B).
ABBVBMYABBV / BMY
Capitalization322B110B293%
EBITDA17.2B19.4B89%
Gain YTD9.314-3.670-254%
P/E Ratio66.4613.73484%
Revenue54.3B45B121%
Total Cash12.8B12.3B104%
Total Debt59.4B41.5B143%
FUNDAMENTALS RATINGS
ABBV vs BMY: Fundamental Ratings
ABBV
BMY
OUTLOOK RATING
1..100
7659
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
664
SMR RATING
1..100
2739
PRICE GROWTH RATING
1..100
5262
P/E GROWTH RATING
1..100
791
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (7) in the Pharmaceuticals Major industry is in the same range as ABBV (16). This means that BMY’s stock grew similarly to ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (64). This means that ABBV’s stock grew somewhat faster than BMY’s over the last 12 months.

ABBV's SMR Rating (27) in the Pharmaceuticals Major industry is in the same range as BMY (39). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.

ABBV's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as BMY (62). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.

ABBV's P/E Growth Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (91). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVBMY
RSI
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
42%
Bullish Trend 2 days ago
56%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
58%
MACD
ODDS (%)
Bullish Trend 2 days ago
56%
Bearish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
53%
Bearish Trend 2 days ago
51%
Advances
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 4 days ago
57%
Declines
ODDS (%)
Bearish Trend 11 days ago
47%
Bearish Trend 2 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
66%
Aroon
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
42%
View a ticker or compare two or three
Ad is loading...
ABBVDaily Signal changed days agoGain/Loss if shorted
 
Show more...
BMYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NRXP3.120.07
+2.30%
NRX Pharmaceuticals
BK57.950.51
+0.89%
Bank of New York Mellon Corp
REFI15.710.03
+0.19%
Chicago Atlantic Real Estate Finance
KRP15.95-0.06
-0.37%
Kimbell Royalty Partners LP
AEL55.99-0.26
-0.46%
American Equity Investment Life Holding Company

ABBV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
-1.03%
PFE - ABBV
54%
Loosely correlated
-0.19%
JNJ - ABBV
39%
Loosely correlated
-0.69%
AMGN - ABBV
33%
Loosely correlated
-0.19%
MRK - ABBV
33%
Loosely correlated
+0.09%
GSK - ABBV
29%
Poorly correlated
-0.92%
More

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with JNJ. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then JNJ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
-0.27%
JNJ - BMY
39%
Loosely correlated
-0.69%
PFE - BMY
36%
Loosely correlated
-0.19%
BIIB - BMY
34%
Loosely correlated
+4.56%
GILD - BMY
33%
Loosely correlated
+0.07%
MRK - BMY
33%
Poorly correlated
+0.09%
More